Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 3633

Sort by

Sort Order Select

Journal Articles

The journey of a thousand miles begins with 1 step

Luca Malcovati

Blood (2021) 138 (10): 824–826.

https://doi.org/10.1182/blood.2021012304

Published: 2021

Journal Articles

What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms

Maria Teresa Voso, Giulia Falconi, Emiliano Fabiani

Blood (2021) 138 (9): 749–757.

https://doi.org/10.1182/blood.2021010764

Published: 2021

Journal Articles

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation

Blood (2021) 137 (23): 3212–3217.

https://doi.org/10.1182/blood.2021010867

Published: 2021

Includes: Supplemental data

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

Leukemia secondary to myeloproliferative neoplasms

Andrew J. Dunbar, Raajit K. Rampal, Ross Levine

Blood (2020) 136 (1): 61–70.

https://doi.org/10.1182/blood.2019000943

Published: 2020

Journal Articles

Introduction to a How I Treat series on major complications after allogeneic stem cell transplantation

Robert Zeiser

Blood (2020) 135 (19): 1609.

https://doi.org/10.1182/blood.2020005811

Published: 2020

Journal Articles

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Blood (2020) 135 (9): 680–688.

https://doi.org/10.1182/blood.2019002959

Published: 2020

Includes: Supplemental data

Journal Articles

Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1/2 multicenter trial

Régis Peffault de Latour, Sylvie Chevret, Anna Lisa Ruggeri, Felipe Suarez, Laetitia Souchet, David Michonneau, Flore Sicre de Fontbrune, Tereza Coman, Nathalie Dhedin, Marie Thérèse Rubio, Stéphanie Nguyen, Mohamad Mohty, Gérard Socié

Blood (2020) 135 (3): 227–229.

https://doi.org/10.1182/blood.2019000358

Published: 2020

Includes: Supplemental data

Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

Blood (2019) 134 (Supplement_1): 565.

https://doi.org/10.1182/blood-2019-124994

Published: 2019

Journal Articles

Influence of Bone Marrow Stromal and Leukemic Cells on Cytarabine Chemo-Toxicity in Acute Myeloid Leukemia (AML)

Liana E Gynn, BSc, Elizabeth Anderson, PhD, Gareth M Robinson, PhD, Sarah Anne Wexler, MBBS, MRCP, FRCPath, Gillian Upstill-Goddard, Christine Cox, Rhys Gareth Morgan, PhD, Jennifer E May, PhD BSc

Blood (2019) 134 (Supplement_1): 2492.

https://doi.org/10.1182/blood-2019-122891

Published: 2019

Journal Articles

An Ongoing Global, Longitudinal, Observational Study of Patients with Pyruvate Kinase Deficiency: The PEAK Registry

Rachael F. Grace, MD, Paola Bianchi, BSc, PhD, Bertil Glader, MD PhD, Andreas Glenthøj, MD PhD, Bryan Jones, PhD, Hitoshi Kanno, MD PhD, Kevin H. M. Kuo, MDMSc,FRCPC, D. Mark Layton, MB ChB, Eduard J. van Beers, MD PhD, Joan-Lluis Vives Corrons, MD PhD, Tu Xu, MS, PhD

Blood (2019) 134 (Supplement_1): 2223.

https://doi.org/10.1182/blood-2019-123059

Published: 2019

Journal Articles

Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Ulrich Jaeger, MD, Nina Worel, MD, Joseph P. McGuirk, DO, Peter A. Riedell, MD, Isabelle Fleury, MD, Peter Borchmann, MD, Jufen Chu, PhD, Ahmed M Abdelhady, PhD, Alessandra Forcina, MD, Lida Bubuteishvili Pacaud, MD, Edmund K. Waller, PhDMD

Blood (2019) 134 (Supplement_1): 5325.

https://doi.org/10.1182/blood-2019-129120

Published: 2019

Journal Articles

Real-World Utilization of Midostaurin Among Patients with Systemic Mastocytosis (SM)

Ajeet Gajra, MD FACP, Andrew J Klink, PhD MPH, Dhruv Chopra, MS, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 5378.

https://doi.org/10.1182/blood-2019-131028

Published: 2019

Journal Articles

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Gemcitabine and Oxaliplatin in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Christine Burnett, Thomas Strack, MD, Tara Lehner, MS, PMP, Jack P Higgins, PhD, Deborah A. Katz, MD, Matthew S. McKinney, MD

Blood (2019) 134 (Supplement_1): 5322.

https://doi.org/10.1182/blood-2019-124890

Published: 2019

Journal Articles

Hematopoietic Stem Cell Transplantation in Βthalassemia Major: The Egyptian Outcome

Amal El-Beshlawy, MD, Amina AbdelSalam, MD, Gamal Fathy, MD, Khaled M. Salamaa, MD, Mona El ghamrawy, MD, Samar S. Ramadan, M.Sc., Alaa M. Elhaddad, MD

Blood (2019) 134 (Supplement_1): 5732.

https://doi.org/10.1182/blood-2019-124398

Published: 2019

Journal Articles

Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing HMA

Brian J Ball, Christopher Famulare, MS, Eytan M. Stein, MD, Martin S. Tallman, MD, Saar I. Gill, MD PhD, Benjamin M Manning, MD PhD, Jamie Koprivnikar, MD, James McCloskey, MD, Rebecca Testi, NP-C, BSN, RN, MSN, OCN, Najla Al Ali, M.Sc, David A Sallman, MD, Eric Padron, MD, Aaron D Goldberg, MD PhD, Rami S. Komrokji, MD

Blood (2019) 134 (Supplement_1): 4241.

https://doi.org/10.1182/blood-2019-125113

Published: 2019

Journal Articles

Outcomes of Allogeneic Stem Cell Transplantation in Patients with Myelofibrosis: A Single Institution Experience

Sajjad Akbar Bhatti, MBBS, Abdulraheem Yacoub, MD, Anurag K. Singh, MD

Blood (2019) 134 (Supplement_1): 5740.

https://doi.org/10.1182/blood-2019-129505

Published: 2019

Journal Articles

Conditioning Regimen Intensity May Affect Outcome in MDS Patients Undergoing Allogeneic Stem Cell Transplantation, Depending on MDS Subgroup

Barry S. Skikne, MD, Anurag K. Singh, MD, Sunil Abhyankar, MD, Tara L. Lin, MD, Leyla Shune, MD, Neil Dunavin, MD, Ajoy L. Dias, MD, Brian McClune, DO, Abdulraheem Yacoub, MD, Clint Divine, Haitham Abdelhakim, MD, Siddhartha Ganguly, MD, Jennifer Hanses, Carol E Webb, BA, Joseph P. McGuirk, DO

Blood (2019) 134 (Supplement_1): 5743.

https://doi.org/10.1182/blood-2019-130828

Published: 2019

Journal Articles

Chronic Myeloid Leukemia in Adolescents and Young Adults: A Single Institute Experience

Mohamed A Yassin, MBBS, MSc, Mohammad Abdul-Jaber Abdulla, MD, Prem Chandra, PhD, Mahmood B Aldapt, MD, Yasser Hamad, MSC, Susanna Jane Akiki, PhD, Nancy Kassem, BSC, Abdulqadir Jeprel Nashwan, BSN, MSN, Ula Nur, PhD

Blood (2019) 134 (Supplement_1): 5915.

https://doi.org/10.1182/blood-2019-126622

Published: 2019

Journal Articles

Molecular MRD Monitoring Is Feasible in the Majority of Children with AML and Is Highly Predictive of Outcome: Results from the International MyeChild01 Study

Blood (2019) 134 (Supplement_1): 1393.

https://doi.org/10.1182/blood-2019-125257

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The journey of a thousand miles begins with 1 step

What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Leukemia secondary to myeloproliferative neoplasms

Introduction to a How I Treat series on major complications after allogeneic stem cell transplantation

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1/2 multicenter trial

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

Influence of Bone Marrow Stromal and Leukemic Cells on Cytarabine Chemo-Toxicity in Acute Myeloid Leukemia (AML)

An Ongoing Global, Longitudinal, Observational Study of Patients with Pyruvate Kinase Deficiency: The PEAK Registry

Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Real-World Utilization of Midostaurin Among Patients with Systemic Mastocytosis (SM)

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Gemcitabine and Oxaliplatin in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Hematopoietic Stem Cell Transplantation in Βthalassemia Major: The Egyptian Outcome

Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing HMA

Outcomes of Allogeneic Stem Cell Transplantation in Patients with Myelofibrosis: A Single Institution Experience

Conditioning Regimen Intensity May Affect Outcome in MDS Patients Undergoing Allogeneic Stem Cell Transplantation, Depending on MDS Subgroup

Chronic Myeloid Leukemia in Adolescents and Young Adults: A Single Institute Experience

Molecular MRD Monitoring Is Feasible in the Majority of Children with AML and Is Highly Predictive of Outcome: Results from the International MyeChild01 Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only